Kornimate/medical-research-clean huggingface dataset:
split-thickness skin graft donor site wound healing study

Conditions: Split-thickness Skin Graft Donor Sites

Summary: the purpose of this research study is to discover whether instruments widely used in skin research can be used to measure wound healing in split thickness skin graft donor sites and whether these instruments can detect differences in healing when two different dressing products are used.

currently there is no standard treatment to promote wound healing for split thickness skin graft donor sites and healing is determined based on clinical observation of the graft donor site and clinical judgement. here we propose to use two instruments commonly used in skin research to measure wound healing. this study will validate the use of these two instruments, one that measures transepidermal water loss and the other that measures skin pigmentation to determine healing. to further validate the use of these instruments we will determine if these instruments can detect differences between two different wound dressing products that have been previously reported to heal skin graft donor sites at different rates.

Eligibility criteria:
inclusion criteria: * participants 18 years of age and over who have a split-thickness skin graft donor site. exclusion criteria: * individuals under 18 years of age. * individuals who do not have a split thickness skin graft donor site.

Keywords: wound healing skin graft donor site donor site transepidermal water loss
the born in guangzhou cohort study (bigcs)

Conditions: Intrauterine Hyperglycemia; Pregnancy Outcomes; Neurodevelopment; Immune Development; Childhood Obesity; Host and Microbiome

Summary: the born in guangzhou cohort study (bigcs) was established to investigate the short- and long-term effects of exposure in early life on health consequences in guangzhou, china. data are collected regarding environmental, occupational and lifestyle exposures as well as health outcomes in later life. biological samples including blood and tissue samples are also collected from the participants.

over the past three decades, china is undergoing rapidly economic development. at the same time, the western diet and urban lifestyle has been more common than before, which may lead to an increase of incidence of non-communicable chronic diseases, such as diabetes and malignancies. notably, the current generation of chinese adults, particularly those in their middle age or older, were born in an era where hardship and rationing was the norm and witnessed a social and epidemiological transition that might have a profound effect on their present health. in contrast, the younger generation is raised in relative material abundance, under the influence of traditional chinese values such as a strong family orientation and an emphasis on academic success. a birth cohort with would provide an opportunity to examine the short- and long-term effects of exposure in early life on health consequences in this younger generation, in the context of rapid development in china.

Eligibility criteria:
inclusion criteria: * pregnant women with \<20 weeks of gestation * pregnant women intended to eventually deliver in guangzhou women and children's medical center * permanent residents or families intended to remain in guangzhou with their child for ≥3 years
efficiency of surgical treatment for lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: decompression surgery has proved to be effective for lumbar spinal stenosis (lss) with persistent pain. but the efficiency of the surgery for degenerated lss remain uncertain and is the subject of this study. this is a multiple center open-label randomised trial. patients were randomly allocated to surgical group or a nonoperative group. because of the procedure , neither patients nor investigators were blinded. the primary outcome is the change of symptom measure by the oswestry disability index 6, 12, and 24 months after procedure.

this study will use a randomised controlled trial to access the efficiency of the surgery for degenerated lss. patients aged 50 years or older, had lss will be invited to take part. patients will be randomised divided into 2 arms. the participants in the intervention arm will have decompression surgery ; those randomised to the control arm will receive current standard conservative treatment methods. patients were clinically assessed at baseline (the day of surgery or treatment), and at 6,12 and 24 months afterwards. the primary outcome will be the pain release , categorised according to oswestry disability index.

Eligibility criteria:
inclusion criteria: * clinical symptoms: back pain radiation to lower limbs or buttocks; fatigue or loss of sensation in the lower limbs aggravated by walking. * persistent pain without progressive neurologic dysfunction * duration of symptoms and signs for more than 6 months * severity of the disease justifying either surgical or nonoperative treatment exclusion criteria: * severe lss with intractable pain and progressive neurologic dysfunction, suggesting forthcoming surgical treatment * spinal stenosis not caused by degeneration * lumbar herniated disc diagnosed during the last 12 months * neurologic disease causing impaired function of the lower limbs

Keywords: surgery decompression
urinary urinary nerve growth factor (ngf) as a biomarker for mixed urinary incontinence

Conditions: Mixed Urinary Incontinence

Summary: female urinary incontinence (ui) can be caused by pure stress ui (sui), pure urgency ui (uui) and mixed sui and uui (mui). clinically it might not be that easy to separate mui and sui. patients might perceive urgency when they have an incompetent urethra and a full bladder. urinary tract nerve growth factor (ngf)is produced by bladder urothelium and smooth muscle. increased levels of ngf have been reported in the bladder tissue and urine of patients with overactive bladder (oab). if the urinary levels of ngf differ among women with pure sui and mui, then urinary ngf level might be a biomarker in the differential diagnosis of mui in women. also, decreased urinary ngf level was reported in oab patients of whom the symptoms were improved. so, we might expect that the remnant oab symptom including urgency incontinence can be improved, if the urinary ngf levels decrease after midurethral slings for sui in mui patients. we aimed to explore the value of the urinary ngf as a biomarker for differential diagnosis and as a prognostic marker for predicting the improvement of oab symptom after midurethral slings.


Eligibility criteria:
inclusion criteria: * women aged 18 or over 18 years with mui for 3 or over 3 months * proven sui by urodynamic study (uds)or stress test * abdominal leak point pressure (alpp)of 120 or less than 120cmh2o in uds * symptoms verified using 5 day bladder diary as below i) number of urgency incontinence; 3 or more than 3/5days ii) number of micturition; 8 or more than 8/24hrs iii) number of urgency; 2 or more than 2/24hrs * women who cannot be pregnant or do not have plan to be pregnant * ability and willingness to correctly complete the micturition diary and questionnaire * capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits exclusion criteria: * the subject has wbc≧3, albumin≧+1, nit ≧+1 upon urinalysis * on an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study * patient has a significant pelvic orgen prolapse (pop) of ics stage 3 or over 3. * patients with combined pop surgery. * patients with bladder outlet obstruction on uds or physical exam * patients with detrusor underactivity * diagnosed or suspected interstitial cystitis or bladder cancer * history of radiation therapy on pelvic cavity * patients with neurologic condition which can affect lower urinary tract function * history of urogenical malignancy within recent 2 years * treatment within the 14 days preceding enrollment, or expected to initiate treatment during the study with: i)any anticholinergic drugs and any drug treatment affecting lower urinary tract function estrogen treatment started more than 2 months prior to inclusion is allowed. ii) electrostimulation, bladder training, electromagnetic treatment * patient is on anti-coagulation therapy. * any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
study of kinetics and efficacy of the immune response against covid-19 among hospital staff

Conditions: Sars-CoV2

Summary: covid-19 is a pathology linked to the sars-cov-2 virus, a new virus of the coronaviridae family that emerged in china in december 2019 before rapidly becoming a pandemic according to the who on march 11, 2020. the epidemic affected france from february 2020. on february 24, a patient hospitalized at percy hospital was the cause of a major nosocomial epidemic, potentially responsible for more than 250 symptomatic people in the hospital as of april 6. the outbreak was identified by percy hospital management on march 16, and barrier measures were immediately put in place. from march 20, a mixed investigation unit set up a chain of nasopharyngeal swabs for percy hospital staff. a covid-19 case reporting unit was set up at percy hospital in response to the identification of the outbreak within the hospital. this unit carried out rapid identification and regular follow-up until the return to work of the staff. thus all symptomatic patients are identified and the covid-19 case census cell will follow all percy hospital staff, including volunteers recruited to deal with the epidemic, throughout the duration of the epidemic. this population, captive by nature, will be one of the few described in the world during this epidemic. current data on short-, medium- and long-term immunity induced by covid-19 infection are fragmentary, as is the existence of a large asymptomatic population, making it difficult to cut the chains of transmission in the absence of an effective diagnostic tool. another important issue is the quality of immunity induced by the infection, as it conditions the future of the pandemic, which could become endemic and recurrent if immunity were not sterilizing. as yet unpublished data in primates show that in the primate model re-infection is not possible in the short term, while patients cured from the wuhan epidemic seem to be detected again positive for virus shedding. the objective of this study is to characterize the immunity (systemic and local) induced by sars-cov-2 infection among percy hospital staff who are at high risk of contamination even in a period of confinement.


Eligibility criteria:
inclusion criteria: * 18 years of age or older; * military or civilian or contactual volunteer on duty at percy hospital during the covid-19 pandemic. exclusion criteria: * individuals who have displayed a severe form of early-onset covid-19 who required intensive care management or hospitalization; * presence of factors modulating immunity with congenital or acquired immunosuppression: * medication: cancer chemotherapy, immunosuppressive drugs, biotherapy, corticosteroids * uncontrolled hiv infection or cd4 \<200/mm3 infection * history of solid organ or hematopoietic stem cell transplants
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for naion

Conditions: Eye Diseases; Retinitis Pigmentosa; Diabetic Retinopathy; Macular Degeneration; Traumatic Optic Neuropathy; Optic Atrophy

Summary: this trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy

this patient funded trial aims to study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (uc-mscs) for the treatment of non-arteritic ischemic optic neuropathy. the total dose will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. for patients with more severe disease an autologous effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Eligibility criteria:
inclusion criteria: * diagnosis of naion (non-arteritic ischemic optic neuropathy) * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: eye diseases retinitis pigmentosa stem cell treatment diabetic retinopathy macular degeneration traumatic optic neuropathy optic atrophy
thromboprophylaxis of venous thromboembolism in acutely-ill medical inpatients with thrombocytopenia

Conditions: Medical Patient; Thrombocytopenia

Summary: fondaparinux is a parenteral anticoagulant drug approved for the prophylaxis of venous thromboembolism in high risk medical patients. a relevant proportion of these patients have renal insufficiency and/or thrombocytopenia which represent independent risk factors for bleeding. the risk of bleeding may be increased when fondaparinux is administered to patients with a reduced renal function and/or low platelet count. a lower dose of fondaparinux, 1.5 mg daily, has been approved for patients with renal insufficiency defined by a creatinine clearance between 20 and 50 ml/min. however, to our knowledge, there are no clinical studies that have specifically evaluated prophylaxis with fondaparinux in acutely-ill medical patients with a moderate to severe thrombocytopenia. the scope of this study is to evaluate the safety of fondaparinux in high risk hospitalized medical patients with a moderate to severe thrombocytopeniada defined by a platelet count between 100,000/ul and 30,000/ul.


Eligibility criteria:
inclusion criteria: * age above 18 years; * hospitalization in an internal medicine unit and a barbar score of 4 points or above * platelet count between 100,000/ul and 30,000/ul * written informed consent exclusion criteria: * active bleeding or bleeding within the previous 3 months; * known bleeding diathesis; * active gastroduodenal ulcer; * severe renal insufficiency defined by a creatinine clearance below 20 ml/min; * ongoing treatment with unfractionated heparin, low-moleculr-weight heparin, fondaparinux, or oral anticoagulants trattamento in corso con eparina non * prophylaxis with unfractionated heparin, low-moleculr-weight heparin, or fondaparinux for more than 48 hours; * double antiplatelet therapy or acetylsalicylic acid at daily doses above 165 mg; * planned invasive procedure during the period of thromboprophylaxis; * hemoglobin values below 9 g/dl; * ast or alt above 2 times the uper limit of normal; * pregnancy or breast feeding; * life expectancy lower than 1 month

Keywords: fondaparinux medical patient vein thromboembolism prophylaxis thrombocytopenia
applications of nanotechnology and chemical sensors for the detection and identification of chronic sinusitis subtypes by respiratory samples

Conditions: CRS

Summary: professor hossam haick from the technion, developed an electronic nose for diagnosis of diseases via breath samples. biomarkers from nose and sinuses and upper respiratory tract can be detected by "electronic nose". identification of biomarkers from nose and sinuses and upper respiratory tract can differentiate between the subtypes of crs (chronic rhinosinusitis) and may serve as markers for disease (vs controls), of disease activity (predicting aggressive disease course, predicting malignant vs benign nasal "polyps", as inverted papillpma or carcinoma; predicting response to therapy (steroid , antibiotics, nasal wash, surgery).

professor hossam haick from the technion, developed an electronic nose for diagnosis of diseases via breath samples. biomarkers from nose and sinuses and upper respiratory tract can be detected by "electronic nose". identification of biomarkers from nose and sinuses and upper respiratory tract can differentiate between the subtypes of crs (chronic rhinosinusitis) and may serve as markers for disease (vs controls), of disease activity (predicting aggressive disease course, predicting malignant vs benign nasal "polyps", as inverted papillpma or carcinoma; predicting response to therapy (steroid , antibiotics, nasal wash, surgery). the aim of this study is to evaluate various crs diseases with the electronic nose trying to better differentiate crswpolyps , crs without polyps, pcd, afs, vasculitis (as wegener granulomatosis) and allergic rhinitis with crs. for that reason samples were taken from patients from different groups of "crs patients": 1. crswpolyps with no eosonophilia , 2. crswpolyps with eosonopholia, 3. crs without polyps, 4. pcd, 5. afs, 6. allergic rhinitis and 7. control subjects.

Eligibility criteria:
inclusion criteria: 1. crs patients that presented in the rhinologic clinic at the hillel yaffe medical center. crs patients that never had fess - endoscopic sinus surgery. 2. willing and able to give inform consent control subjects: 1. age and gender match control individuals that do not have crs or any other condition that is defined as nasal disease. these individuals will be recruited as "healthy population reference" group. 2. willing and able to give informed consent exclusion criteria: 1. patients age 18 or less, pregnant women 2. presence of hiv, hepatitis or any other potentially severe and infectious disease. patient that had sinus surgery.

Keywords: chronic rhinosinusitis, nasal polyposis
the inspiring action to prevent diabetes intervention

Conditions: PreDiabetes

Summary: this research is studying how to help increase uptake of and engagement in formal diabetes prevention programs to improve healthy behaviors among adults with pre diabetes to reduce risk of getting diabetes. this project will compare the diabetes prevention program (dpp) to participating in the dpp program plus two extra pieces (inspira). the 2 additional pieces in the dpp plus program includes getting matched with someone else in the program to provide each other support along with a chance to earn healthy food vouchers. eligible participants will be randomized to one of the two groups and be asked to participate for approximately 6 months.


Eligibility criteria:
inclusion criteria: * english or spanish-speaking * body mass index (bmi) \> 24.9 kilograms/meters squared (kg/m2) * the most recent a1c test, completed in 60 days or fewer prior to enrollment, is 5.7%-6.4% exclusion criteria: * diagnosed with schizophrenia * active alcohol or other drug abuse * are pregnant or planning pregnancy in next 6 months * will not be in local area in six months * will not be able to attend sessions, in-person or remotely, for three more weeks

Keywords: diabetes prevention program behaviors weight loss healthy lifestyle changes peer partner
levosimendan versus dobutamine in shock patients

Conditions: Cardiogenic Shock; Septic Shock

Summary: the purpose of the study is to compare the efficacy of levosimendan with that of dobutamine in patients with unstable hemodynamics (shock).


Eligibility criteria:
inclusion criteria: * reduced left ventricular systolic function * hypotension * anuria or oligouria exclusion criteria: * less than 18 years old * pregnant * uncorrected valvular stenosis * hypertrophic obstructive cardiomyopathy (hocm) * third degree av block

Keywords: shock levosimendan inotropes dobutamine heart failure sepsis
role of mechanical load on metabolic exercise adaptations in response to weight loss in obese adolescents: the powell study

Conditions: Pediatric Obesity

Summary: while interdisciplinary weight loss intervention have been shown successful among adolescents with obesity, a weight regain is most of the time observed within the following weeks or months. the aim of the present project will be to better identify the independent role played by both the metabolic and mechanical load and their modification during weight loss, on the energy expenditure and energy metabolism of adolescents with obesity.

a total of 28 adolescents with obesity will be recruited from our local inpatient pediatric obesity centers. before their weight loss intervention the adolescents will complete two experimental visits. during the first visit, anthropometric and body composition measurements will be performed. then the participants will be asked to complete a walking exercise on a treadmill during the second visit. their energy expenditure and substrate oxidation will be assessed by indirect calorimetry. they will have to walk at 5 different walking speeds. then, they will follow a 12-week weight loss intervention. by the end of this intervention, their body composition will be assessed and they will be asked to perform the same walking exercise. on a separate occasion (randomly assigned) they will have to repeat this walking exercise while carrying a load corresponding of their weight loss.

Eligibility criteria:
inclusion criteria: * being aged 12-16 years old * no contraindication to physical exercise * no cardiovascular disease * bmi above the 97th percentile * candidate to a weight loss intervention exclusion criteria: * surgery and medical conditions preventing them to perform the intervention * weight loss during the previous 6 months * medication that could interfere with energy metabolism. * pregnancy * regular tobacco and alcool use

Keywords: energy expenditure weight loss obesity adolescents
extension study to evaluate long term safety of denosumab in subjects undergoing adt for non-metastatic prostate cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors

Summary: the purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.


Eligibility criteria:
inclusion criteria: * subjects must be currently participating in the 20040138 amgen study * subjects must sign the informed consent before any study specific procedures are performed. exclusion criteria * subjects with any prior diagnosis of bone metastasis * known hypocalcemia * developed sensitivity to mammalian cell derived drug products during the 20040138 study * currently receiving any investigational product other than denosumab or having received any investigational product during the 20040138 study * any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures

Keywords: androgen deprivation therapy for non-metastatic prostate cancer